Detalhe da pesquisa
1.
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(12): 1334-1348, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38039991
2.
Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitors.
Bioorg Med Chem Lett
; 91: 129352, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37270074
3.
Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors.
Bioorg Med Chem Lett
; 30(22): 127523, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32877741
4.
Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase.
Bioorg Med Chem Lett
; 30(18): 127393, 2020 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32721854
5.
Optimization of a series of potent, selective and orally bioavailable SYK inhibitors.
Bioorg Med Chem Lett
; 30(19): 127433, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32717371
6.
Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors.
Biochem J
; 452(3): 499-508, 2013 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23581296
7.
TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.
Ther Adv Med Oncol
; 16: 17588359241248336, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38686016
8.
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
J Clin Oncol
; 41(1): 43-53, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35737919
9.
Inhibition of PI3Kß signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Mol Cancer Ther
; 14(1): 48-58, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25398829
10.
Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.
J Med Chem
; 56(5): 2059-73, 2013 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-23394218